Laryngorhinootologie 2024; 103(S 02): S322-S323
DOI: 10.1055/s-0044-1785093
Abstracts │ DGHNOKHC
Rhinologie: Allergology/Immunology

Allergen Immunotherapy under protective biological treatment with Omalizumab

Authors

  • Michael Krokenberger

    1   Technische Universität München, Hals-, Nasen-, Ohrenklinik und Poliklinik, München

  • Sebastian Kotz

    1   Technische Universität München, Hals-, Nasen-, Ohrenklinik und Poliklinik, München

  • Barbara Wollenberg

    1   Technische Universität München, Hals-, Nasen-, Ohrenklinik und Poliklinik, München

  • Adam Chaker

    2   Technische Universität München, Zentrum für Allergie und Umwelt, München
Further Information
Also available at
 
 

    Background Omalizumab (Xolair®​; Novartis) is a recombinant IgG1 monoclonal antibody that selectively binds to human IgE and is approved for the treatment of allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps. Since its approval, the use of Omalizumab has been investigated in clinical studies for food allergies, atopic dermatitis, and eosinophilic gastritis. However, no approval exists for these indications. Allergen immunotherapy (AIT) is the only causal therapy used for allergic rhinitis (AR) and asthma. Systemic side effects are rare but can limit therapy.

    Material and methods We present 5 patient cases as use-cases over the long term for the targeted use of Omalizumab in AIT.

    Results Over a period of 2 to 5 years, none of the patients showed a severe anaphylactic reaction. Isolated skin redness at the injection site occurred occasionally. Rhinoconjunctival symptoms regressed while comorbid conditions such as asthma or chronic spontaneous urticaria improved simultaneously.

    Conclusion Simultaneous administration of Omalizumab enables a subcutaneous AIT with fewer side effects. The presented results show that in cases of T2 comorbidities otherwise not adequately controlled or severe side effects under AIT, the administration of Omalizumab is a rational option.


     

    Publication History

    Article published online:
    19 April 2024

    © 2024. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany